PolyPid Ltd.: peers
PolyPid Ltd. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
PolyPid Ltd., Sol-Gel Technologies, Mediwound, Compugen Ltd., Intercure Ltd., Solegreen Ltd, Nasus Pharma Ltd.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | PolyPid Ltd.base PYPD · 🇮🇱 IL Percentile in Healthcare Percentile in Israel | Sol-Gel Technologies 4SG.F · 🇮🇱 IL Percentile in Healthcare Percentile in Israel | Mediwound M8W.F · 🇮🇱 IL Percentile in Healthcare Percentile in Israel | Compugen Ltd. CGEN.TA · 🇮🇱 IL Percentile in Healthcare Percentile in Israel | Oramed Pharmaceuticals Inc. ORMP · 🇮🇱 IL Percentile in Healthcare Percentile in Israel | Intercure Ltd. INCR · 🇮🇱 IL Percentile in Healthcare Percentile in Israel | Solegreen Ltd SLGN.TA · 🇮🇱 IL Percentile in Healthcare Percentile in Israel | Nasus Pharma Ltd. NSRX · 🇮🇱 IL Percentile in Healthcare Percentile in Israel | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $103 MAug 1, 2026 · Market data3rd of 8 | $99 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one5th of 8 | $88 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one6th of 8 | $174 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one2nd of 8 | $177 MOct 27, 2026 · Market data1st of 8 | $51 MAug 1, 2026 · Market data7th of 8 | $103 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one4th of 8 | $45 MAug 1, 2026 · Market data8th of 8 | $101 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | $19 MFY2025 · SEC4th of 6 | $17 MFY2025 · SEC5th of 6 | $73 MFY2025 · SEC2nd of 6 | $2 MFY2025 · SEC6th of 6 | $65 MFY2024 · SEC3rd of 6 | —— | $1.2 BFY2025 · SEC1st of 6 | $42 M6 ranked |
| Net income (Higher is better) | $-34 MFY2025 · SEC7th of 7 | $-6 MFY2025 · SEC4th of 7 | $-24 MFY2025 · SEC6th of 7 | $35 MFY2025 · SEC2nd of 7 | $64 MFY2025 · SEC1st of 7 | $-18 MFY2024 · SEC5th of 7 | —— | $-6 MFY2025 · SEC3rd of 7 | $-6 M7 ranked |
| Employees (Better neither way: ranked highest first) | 59December 31, 2025 · Profileonly one with it | —— | —— | —— | —— | —— | —— | —— | 59— |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | +68.0%FY2025 · SEC2nd of 488th89th | -16.1%FY2025 · SEC3rd of 411th13th | +161.2%FY2025 · SEC1st of 495th95th | ———— | -33.0%FY2024 · SEC4th of 47th4th | ———— | ———— | +25.9%4 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | +71.0%FY2025 · SEC2nd of 493rd95th | -13.8%FY2025 · SEC4th of 410th12th | +113.3%FY2025 · SEC1st of 496th99th | ———— | -1.7%FY2024 · SEC3rd of 423rd27th | ———— | ———— | +34.6%4 ranked |
| Earnings per share growth (Higher is better) | -57.4%FY2025 · SEConly one with it7th16th | ———— | ———— | ———— | ———— | ———— | ———— | ———— | -57.4%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | ———— | 19.2%FY2025 · SEC2nd of 48th20th | 87.3%FY2025 · SEC1st of 489th98th | 0.5%FY2025 · SEC4th of 42nd8th | 12.7%FY2024 · SEC3rd of 45th11th | ———— | ———— | 15.9%4 ranked |
| Operating margin (Higher is better) | ———— | -38.9%FY2025 · SEC4th of 634th31st | -149.0%FY2025 · SEC5th of 619th20th | 43.1%FY2025 · SEC1st of 698th98th | -754.5%FY2025 · SEC6th of 62nd4th | -28.1%FY2024 · SEC3rd of 639th34th | ———— | -0.4%FY2025 · SEC2nd of 657th47th | -33.5%6 ranked |
| Net margin (Higher is better) | ———— | -31.6%FY2025 · SEC4th of 537th33rd | -140.8%FY2025 · SEC5th of 519th18th | 48.6%FY2025 · SEC1st of 598th99th | ———— | -28.4%FY2024 · SEC3rd of 539th34th | ———— | -0.5%FY2025 · SEC2nd of 559th49th | -28.4%5 ranked |
| Free cash flow margin (Higher is better) | ———— | 1.4%FY2025 · SEC2nd of 655th46th | -127.5%FY2025 · SEC5th of 619th20th | 43.0%FY2025 · SEC1st of 698th99th | -457.5%FY2025 · SEC6th of 67th5th | -29.9%FY2024 · SEC4th of 633rd34th | ———— | -0.4%FY2025 · SEC3rd of 651st44th | -15.1%6 ranked |
| Return on equity (Higher is better) | -366.4%FY2025 · SEC6th of 63rd2nd | -23.7%FY2025 · SEC4th of 659th42nd | -63.9%FY2025 · SEC5th of 636th32nd | 44.8%FY2025 · SEC1st of 697th99th | 37.0%FY2025 · SEC2nd of 696th97th | -15.6%FY2024 · SEC3rd of 663rd44th | ———— | ———— | -19.7%6 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | 2.8×price Oct 27, 2026 · Market dataonly one with it3rd— | ———— | ———— | ———— | 2.8×— |
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | 88.7×price Oct 27, 2026 · Market dataonly one with it94th96th | 0.8׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | 0.0׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 88.7×— |
| Price to book (Better neither way: ranked highest first) | 9.4׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | ———— | 0.9×price Oct 27, 2026 · Market dataonly one with it17th41st | 0.5׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | 16.3׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 0.9×— |
| Free cash flow yield (Higher is better) | -27.2%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | ———— | -5.2%price Oct 27, 2026 · Market dataonly one with it54th38th | -37.4%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | -10.9%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | -5.2%— |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | ———— | ———— | ———— | 0.3×FY2024 · SEConly one with it38th75th | ———— | ———— | 0.3×— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 2 of 8FY2025 · Scorecard5th of 7 | 8 of 14FY2025 · Scorecard3rd of 7 | 0 of 12FY2025 · Scorecard7th of 7 | 11 of 14FY2025 · Scorecard1st of 7 | 11 of 19FY2025 · Scorecard2nd of 7 | 2 of 13FY2024 · Scorecard6th of 7 | —— | 2 of 6FY2025 · Scorecard4th of 7 | 33% passed7 ranked |
| Valuation checks (Higher is better) | —— | —— | —— | —— | 3 of 5FY2025 · Scorecardonly one with it | —— | —— | —— | 60% passed— |
| Growth checks (Higher is better) | 1 of 2FY2025 · Scorecard4th of 7 | 4 of 6FY2025 · Scorecard3rd of 7 | 0 of 6FY2025 · Scorecard5th of 7 | 6 of 6FY2025 · Scorecard1st of 7 | 2 of 2FY2025 · Scorecard1st of 7 | 0 of 6FY2024 · Scorecard5th of 7 | —— | 0 of 1FY2025 · Scorecard5th of 7 | 50% passed7 ranked |
| Profitability checks (Higher is better) | 0 of 3FY2025 · Scorecard6th of 7 | 2 of 5FY2025 · Scorecard4th of 7 | 0 of 5FY2025 · Scorecard6th of 7 | 4 of 5FY2025 · Scorecard1st of 7 | 3 of 5FY2025 · Scorecard2nd of 7 | 1 of 5FY2024 · Scorecard5th of 7 | —— | 1 of 2FY2025 · Scorecard3rd of 7 | 40% passed7 ranked |
| Financial health checks (Higher is better) | 1 of 2FY2025 · Scorecard2nd of 7 | 1 of 2FY2025 · Scorecard2nd of 7 | 0 of 1FY2025 · Scorecard7th of 7 | 1 of 2FY2025 · Scorecard2nd of 7 | 2 of 3FY2025 · Scorecard1st of 7 | 1 of 2FY2024 · Scorecard2nd of 7 | —— | 1 of 2FY2025 · Scorecard2nd of 7 | 50% passed7 ranked |
| Shareholder returns checks (Higher is better) | 0 of 1FY2025 · Scorecard3rd of 5 | 1 of 1FY2025 · Scorecard1st of 5 | —— | 0 of 1FY2025 · Scorecard3rd of 5 | 1 of 4FY2025 · Scorecard2nd of 5 | —— | —— | 0 of 1FY2025 · Scorecard3rd of 5 | 0% passed5 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | 10.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 4 | —— | —— | —— | 42.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 4 | 1.2%2026-Q2 · 13F4th of 4 | —— | 24.1%2026-Q1 · 13F2nd of 4 | 17.4%4 ranked |
| Institutions holding (Better neither way: ranked highest first) | 252026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 4 | —— | —— | —— | 932026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 4 | 162026-Q2 · 13F3rd of 4 | —— | 92026-Q1 · 13F4th of 4 | 214 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | -3.2 pp2026-Q2 against 2026-Q1 · 13F3rd of 3 | —— | —— | —— | +7.6 pp2026-Q2 against 2026-Q1 · 13F2nd of 3 | —— | —— | +24.1 pp2026-Q1 against 2025-Q4 · 13F1st of 3 | +7.6 pp3 ranked |
| Dividends | |||||||||
| Shareholder yield (Higher is better) | ———— | ———— | ———— | ———— | 2.7%FY2025 · SEConly one with it56th— | ———— | ———— | ———— | 2.7%— |
| Dividend per share (Better neither way: ranked highest first) | —— | —— | —— | —— | $0.25FY2025 · SEConly one with it | —— | —— | —— | $0.25— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = PolyPid Ltd.: How market caps are worked out; Sol-Gel Technologies: How market caps are worked out; Mediwound: How market caps are worked out; Compugen Ltd.: How market caps are worked out; Oramed Pharmaceuticals Inc.: How market caps are worked out; Intercure Ltd.: How market caps are worked out; Solegreen Ltd: How market caps are worked out; Nasus Pharma Ltd.: How market caps are worked out.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| PolyPid Ltd. | — | — | — |
| Sol-Gel Technologies | -38.9%FY2025 | 34th percentile in Healthcaremedian -7.7%, 674 companies | 31st percentile in Israelmedian -0.2%, 67 companies |
| Mediwound | -149.0%FY2025 | 19th percentile in Healthcaremedian -7.7%, 674 companies | 20th percentile in Israelmedian -0.2%, 67 companies |
| Compugen Ltd. | 43.1%FY2025 | 98th percentile in Healthcaremedian -7.7%, 674 companies | 98th percentile in Israelmedian -0.2%, 67 companies |
| Oramed Pharmaceuticals Inc. | -754.5%FY2025 | 2nd percentile in Healthcaremedian -7.7%, 674 companies | 4th percentile in Israelmedian -0.2%, 67 companies |
| Intercure Ltd. | -28.1%FY2024 | 39th percentile in Healthcaremedian -7.7%, 674 companies | 34th percentile in Israelmedian -0.2%, 67 companies |
| Solegreen Ltd | — | — | — |
| Nasus Pharma Ltd. | -0.4%FY2025 | 57th percentile in Healthcaremedian -7.7%, 674 companies | 47th percentile in Israelmedian -0.2%, 67 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | PolyPid Ltd. | Sol-Gel Technologies | Mediwound | Compugen Ltd. | Oramed Pharmaceuticals Inc. | Intercure Ltd. | Solegreen Ltd | Nasus Pharma Ltd. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | $19 MSEC3rd | $17 MSEC4th | $73 MSEC2nd | $2 MSEC5th | — | — | $1.2 BSEC1st |
| 2024 | — | $12 MSEC4th | $20 MSEC3rd | $28 MSEC2nd | — | $65 MSEC1st | — | — |
| 2023 | — | $2 MSEC4th | $19 MSEC3rd | $33 MSEC2nd | $1 MSEC5th | $96 MSEC1st | — | — |
| 2022 | — | $4 MSEC4th | $27 MSEC2nd | $8 MSEC3rd | $3 MSEC5th | $116 MSEC1st | — | — |
| 2021 | — | $31 MSEC2nd | $24 MSEC3rd | $6 MSEC4th | $3 MSEC5th | $68 MSEC1st | — | — |
| 2020 | — | $9 MSEC3rd | $22 MSEC1st | $2 MSEC5th | $3 MSEC4th | $19 MSEC2nd | — | — |
| 2019 | — | $23 MSEC2nd | $32 MSEC1st | — | $3 MSEC3rd | $3 MSEC4th | — | — |
| 2018 | — | $0 MSEC4th | $3 MSEC2nd | $18 MSEC1st | $2 MSEC3rd | — | — | — |
| 2017 | — | $0 MSEC3rd | $3 MSEC1st | — | $2 MSEC2nd | — | — | — |
| 2016 | — | — | $2 MSEC1st | — | $1 MSEC2nd | — | — | — |
| 2015 | — | — | $1 MSEC2nd | $9 MSEC1st | — | — | — | — |
| 2014 | — | — | — | $12 MSEC | — | — | — | — |
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of PolyPid Ltd.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Sol-Gel Technologies4SG.F · 🇮🇱 IsraelSame industry: Biotechnology · Similar size: $99 M market cap against $103 M · Same country: Israel · Ratios of the last two fiscal years on fileMarket cap $99 M (last known, Jul 30, 2023) · revenue $19 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- MediwoundM8W.F · 🇮🇱 IsraelSame industry: Biotechnology · Similar size: $88 M market cap against $103 M · Same country: Israel · Ratios of the last two fiscal years on fileMarket cap $88 M (last known, Jul 30, 2023) · revenue $17 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Compugen Ltd.CGEN.TA · 🇮🇱 IsraelSame industry: Biotechnology · Similar size: $174 M market cap against $103 M · Same country: Israel · Ratios of the last two fiscal years on fileMarket cap $174 M (last known, Jan 5, 2024) · revenue $73 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)In the group
- Oramed Pharmaceuticals Inc.ORMP · 🇮🇱 IsraelSame industry: Biotechnology · Similar size: $177 M market cap against $103 M · Same country: Israel · Ratios of the last two fiscal years on fileMarket cap $177 M (Oct 27, 2026) · revenue $2 M (year to December 2025)96 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)In the group
- Intercure Ltd.INCR · 🇮🇱 IsraelSame industry: Biotechnology · Similar size: $51 M market cap against $103 M · Same country: Israel · Ratios of the last two fiscal years on fileMarket cap $51 M (Aug 1, 2026) · revenue $65 M (year to December 2024)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)In the group
- Solegreen LtdSLGN.TA · 🇮🇱 IsraelSame industry: Biotechnology · Similar size: $103 M market cap against $103 M · Same country: IsraelMarket cap $103 M (last known, Jan 5, 2024)95 of 100 (industry or sector 50 + size 30 + country 15)In the group
- Nasus Pharma Ltd.NSRX · 🇮🇱 IsraelSame industry: Biotechnology · Similar size: $45 M market cap against $103 M · Same country: Israel · Ratios of the last two fiscal years on fileMarket cap $45 M (Aug 1, 2026) · revenue $1.2 B (year to December 2025)95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)In the group
- Protalix BioTherapeutics, Inc.PLX.TA · 🇮🇱 IsraelSame industry: Biotechnology · Similar size: $59 M market cap against $103 M · Same country: IsraelMarket cap $59 M (last known, Dec 25, 2022) · revenue $53 M (year to December 2025)91 of 100 (industry or sector 50 + size 26 + country 15)+ Add
- Pluristem TherapeuticsPSTI.TA · 🇮🇱 IsraelSame industry: Biotechnology · Similar size: $46 M market cap against $103 M · Same country: IsraelMarket cap $46 M (last known, Jan 7, 2022)90 of 100 (industry or sector 50 + size 25 + country 15)+ Add
- Enlivex TherapeuticsENLV.TA · 🇮🇱 IsraelSame industry: Biotechnology · Similar size: $44 M market cap against $103 M · Same country: IsraelMarket cap $44 M (last known, Jul 30, 2023)89 of 100 (industry or sector 50 + size 24 + country 15)+ Add
- Entera Bio Ltd.ENTX · 🇮🇱 IsraelSame industry: Biotechnology · 5.3× larger by market cap · Same country: Israel · Ratios of the last two fiscal years on fileMarket cap $543 M (Oct 30, 2026) · revenue $0 M (year to December 2025)89 of 100 (industry or sector 50 + size 19 + country 15 + figures on file 5)+ Add
- Pluri Inc.PLUR · 🇮🇱 IsraelSame industry: Biotechnology · 6.8× smaller by market cap · Same country: Israel · Ratios of the last two fiscal years on fileMarket cap $15 M (Oct 29, 2026) · revenue $1 M (year to June 2026)88 of 100 (industry or sector 50 + size 18 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.